{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T11:19:33Z","timestamp":1768735173372,"version":"3.49.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T00:00:00Z","timestamp":1670198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Fingolimod (FTY-720) is an immunomodulatory oral agent approved for the treatment of relapsing-remitting multiple sclerosis (RRMS); however, several clinical trials have shown that some recipients may develop macular oedema (ME) as an adverse reaction. As there are no studies assessing the long-term (&gt;\u20091\u2009year) effect of fingolimod on the macula, this study aimed to evaluate the quantitative effect of fingolimod therapy on central macular thickness (CMT) and total macular volume (TMV) over a four-year period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective longitudinal cohort study was performed between January 2014 and December 2018. A total of 21 patients with RRMS receiving fingolimod therapy were recruited and followed-up over 4 years to assess CMT and TMV changes measured using spectral domain optical coherence tomography. A paired sample t-test was used to compare mean CMT and TMV values calculated at baseline prior to the initiation of fingolimod therapy with those observed at three, six, 12, 24, 36 and 48\u2009months of treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>None of the patients developed ME over the four-year study period. In addition, there was no significant difference in baseline mean CMT values and those observed at a four-year follow-up. Although mean TMV values remained constant initially, there was a significant decrease towards the end of the study period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Long-term fingolimod therapy did not result in significant CFT changes. While there was a reduction in TMV towards the end of the study, this is likely due to the degenerative effect of the disease itself on the nerve fibres of the retina.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12886-022-02701-7","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T12:06:09Z","timestamp":1670241969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effect of fingolimod therapy on quantitative macular changes among patients with relapsing-remitting multiple sclerosis: a four-year follow-up study from Oman"],"prefix":"10.1186","volume":"22","author":[{"given":"Aseel A.","family":"Al-Rashdi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buthaina I.","family":"Sabt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah S.","family":"Al-Mujaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,5]]},"reference":[{"key":"2701_CR1","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2.","journal-title":"Lancet Neurol"},{"key":"2701_CR2","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","volume":"78","author":"N Jain","year":"2012","unstructured":"Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection and management. Neurology. 2012;78:672\u201380. https:\/\/doi.org\/10.1212\/WNL.0b013e318248deea.","journal-title":"Neurology"},{"key":"2701_CR3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","volume":"362","author":"JA Cohen","year":"2010","unstructured":"Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. New Engl J Med. 2010;362:402\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0907839.","journal-title":"New Engl J Med"},{"key":"2701_CR4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. New Engl J Med. 2010;362:387\u2013401. https:\/\/doi.org\/10.1056\/NEJMoa0909494.","journal-title":"New Engl J Med."},{"key":"2701_CR5","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1212\/WNL.0000000000000137","volume":"82","author":"G Karlsson","year":"2014","unstructured":"Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674\u201380. https:\/\/doi.org\/10.1212\/WNL.0000000000000137.","journal-title":"Neurology"},{"key":"2701_CR6","doi-asserted-by":"publisher","first-page":"3802","DOI":"10.1093\/ndt\/gfr503","volume":"26","author":"AJ Hoitsma","year":"2011","unstructured":"Hoitsma AJ, Woodle ES, Abramowicz D, Proot P, Vanrenterghem Y, FTY720 Phase II Transplant Study Group. FTY720 combined with tacrolimus in de novo renal transplantation: 1-year, multicenter, open-label randomized study. Nephrol Dial Transplant. 2011;26:3802\u20135. https:\/\/doi.org\/10.1093\/ndt\/gfr503.","journal-title":"Nephrol Dial Transplant"},{"key":"2701_CR7","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1111\/j.1600-6143.2006.01404.x","volume":"6","author":"S Mulgaonkar","year":"2006","unstructured":"Mulgaonkar S, Tedesco H, Oppenheimer F, et al. FTY720\/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am J Transplant. 2006;6:1848\u201357. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01404.x.","journal-title":"Am J Transplant"},{"key":"2701_CR8","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1111\/j.1600-6143.2006.01552.x","volume":"6","author":"M Salvadori","year":"2006","unstructured":"Salvadori M, Budde K, Charpentier B, et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am J Transplant. 2006;6:2912\u201321. https:\/\/doi.org\/10.1111\/j.1600-6143.2006.01552.x.","journal-title":"Am J Transplant"},{"key":"2701_CR9","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1097\/01.tp.0000251718.95622.b3","volume":"82","author":"H Tedesco-Silva","year":"2006","unstructured":"Tedesco-Silva H, Pescovitz MD, Cibrik D, et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation. 2006;82:1689\u201397. https:\/\/doi.org\/10.1097\/01.tp.0000251718.95622.b3.","journal-title":"Transplantation"},{"key":"2701_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1097\/01.tp.0000281385.26500.3b","volume":"84","author":"H Tedesco-Silva","year":"2007","unstructured":"Tedesco-Silva H, Szakaly P, Shoker A, et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation. 2007;84:885\u201392. https:\/\/doi.org\/10.1097\/01.tp.0000281385.26500.3b.","journal-title":"Transplantation"},{"key":"2701_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.msard.2020.102125","volume":"42","author":"LY Goh","year":"2020","unstructured":"Goh LY, Kirthi V, Silber E, Harvey JP, Jackson TL. Real-world incidence of fingolimod-associated macular oedema. Mult Scler Relat Disord. 2020;42:102\u201325. https:\/\/doi.org\/10.1016\/j.msard.2020.102125.","journal-title":"Mult Scler Relat Disord"},{"key":"2701_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1212\/WNL.0b013e31827b9132","volume":"80","author":"R Nolan","year":"2013","unstructured":"Nolan R, Gelfand JM, Green AJ. Fingolimod treatment in multiple sclerosis leads to increased macular volume. Neurology. 2013;80:139\u201344. https:\/\/doi.org\/10.1212\/WNL.0b013e31827b9132.","journal-title":"Neurology"},{"key":"2701_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10792-018-0870-x","volume":"39","author":"M Fruschelli","year":"2019","unstructured":"Fruschelli M, Capozzoli M, Gelmi MC, Masi G, Annunziata P. Longitudinal quantitative assessment of macula during therapy with fingolimod in relapsing-remitting multiple sclerosis. Int Ophthalmol. 2019;39:777\u201381. https:\/\/doi.org\/10.1007\/s10792-018-0870-x.","journal-title":"Int Ophthalmol"},{"key":"2701_CR14","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.5301\/EJO.2010.6050","volume":"21","author":"S Scholl","year":"2011","unstructured":"Scholl S, Augustin A, Loewenstein A, Rizzo S, Kuppermann BD. General pathophysiology of macular edema. Eur J Ophthalmol. 2011;21:S10\u20139. https:\/\/doi.org\/10.5301\/EJO.2010.6050.","journal-title":"Eur J Ophthalmol"},{"key":"2701_CR15","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s40265-013-0055-x","volume":"73","author":"OE Makri","year":"2013","unstructured":"Makri OE, Georgalas I, Georgakopoulos CD. Drug-induced macular edema. Drugs. 2013;73:789\u2013802. https:\/\/doi.org\/10.1007\/s40265-013-0055-x.","journal-title":"Drugs"},{"key":"2701_CR16","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/j.bbalip.2014.06.012","volume":"1841","author":"BA Wilkerson","year":"2014","unstructured":"Wilkerson BA, Argraves KM. The role of sphingosine-1-phosphate in endothelial barrier function. Biochim Biophys Acta. 2014;1841:1403\u201312. https:\/\/doi.org\/10.1016\/j.bbalip.2014.06.012.","journal-title":"Biochim Biophys Acta"},{"key":"2701_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cellsig.2004.08.006","volume":"17","author":"BJ McVerry","year":"2005","unstructured":"McVerry BJ, Garcia JGN. In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cell Signal. 2005;17:131\u20139. https:\/\/doi.org\/10.1016\/j.cellsig.2004.08.006.","journal-title":"Cell Signal"},{"key":"2701_CR18","doi-asserted-by":"publisher","first-page":"135160","DOI":"10.1016\/j.neulet.2020.135160","volume":"735","author":"YJ Li","year":"2020","unstructured":"Li YJ, Shi SX, Liu Q, Shi FD, Gonzales RJ. Targeted role for sphingosine-1-phosphate receptor 1 in cerebrovascular integrity and inflammation during acute ischemic stroke. Neurosci Lett. 2020;735:135160. https:\/\/doi.org\/10.1016\/j.neulet.2020.135160.","journal-title":"Neurosci Lett"},{"key":"2701_CR19","doi-asserted-by":"publisher","first-page":"ii24","DOI":"10.1136\/bjophthalmol-2014-305305","volume":"98","author":"G Trichonas","year":"2014","unstructured":"Trichonas G, Kaiser PK. Optical coherence tomography imaging of macular oedema. Br J Ophthalmol. 2014;98:ii24\u20139. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-305305.","journal-title":"Br J Ophthalmol"},{"key":"2701_CR20","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1093\/brain\/aws098","volume":"135","author":"JM Gelfand","year":"2012","unstructured":"Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain. 2012;135:1786\u201393. https:\/\/doi.org\/10.1093\/brain\/aws098.","journal-title":"Brain"},{"key":"2701_CR21","doi-asserted-by":"publisher","first-page":"e909","DOI":"10.1212\/NXI.0000000000000909","volume":"8","author":"A Abraham","year":"2020","unstructured":"Abraham A, Nicholson L, Dick A, Rice C, Atan D. Intermediate uveitis associated with MS: diagnosis, clinical features, pathogenic mechanisms, and recommendations for management. Neurol Neuroimmunol Neuroinflamm. 2020;8:e909. https:\/\/doi.org\/10.1212\/NXI.0000000000000909.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2701_CR22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/s0161-6420(93)31567-8","volume":"100","author":"SM Malinowski","year":"1993","unstructured":"Malinowski SM, Pulido JS, Folk JC. Long-term visual outcome and complications associated with pars planitis. Ophthalmology. 1993;100:818\u201325. https:\/\/doi.org\/10.1016\/s0161-6420(93)31567-8.","journal-title":"Ophthalmology"},{"key":"2701_CR23","doi-asserted-by":"publisher","first-page":"8344","DOI":"10.1167\/iovs.12-10362","volume":"53","author":"R Herrero","year":"2012","unstructured":"Herrero R, Garcia-Martin E, Almarcegui C, et al. Progressive degeneration of the retinal nerve fiber layer in patients with multiple sclerosis. Invest Ophthalmol Vis Sci. 2012;53:8344\u20139. https:\/\/doi.org\/10.1167\/iovs.12-10362.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2701_CR24","doi-asserted-by":"publisher","unstructured":"Karakosta C, Kourentis C. Fingolimod-associated macular edema: a case report of late onset. Eur J Ophthalmol. 2021:1120672121999632. https:\/\/doi.org\/10.1177\/1120672121999632.","DOI":"10.1177\/1120672121999632"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02701-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-022-02701-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-022-02701-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T18:06:24Z","timestamp":1670522784000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-022-02701-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,5]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2701"],"URL":"https:\/\/doi.org\/10.1186\/s12886-022-02701-7","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,5]]},"assertion":[{"value":"5 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the Medical Research & Ethics Committee of the College of Medicine & Health Sciences at Sultan Qaboos University (MREC approval #1946). Further authorization was obtained from the hospital information system to access patients\u2019 medical records. Informed consent was obtained from all patients. All methods were performed in accordance with the relevant guidelines and regulations adhered to the tenets of the Declaration of Helsinki as amended in 2008.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"NA (Not Applicable).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors has proprietary interests or any potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"470"}}